Before the introduction of the Hercep Test, it was known that a variable subset of cervical carcinomas ranging from 8% to 77% express HER2 as evaluated by diverse methods [6-14] and that in some studies its overexpression has shown to confer a worse prognosis [7-9,13]. Here, ERBB2 is linked to cervical carcinoma.